Product Description

🔹 Product Overview
Raccase 1.5 mg Vial is a prescription oncology supportive care medicine used to manage high uric acid levels caused by cancer chemotherapy.
Contains Rasburicase 1.5 mg, a recombinant urate oxidase enzyme that rapidly lowers uric acid levels in the blood.
Commonly used in patients at risk of Tumor Lysis Syndrome (TLS) during cancer treatment.

🔹 Key Uses
Treatment and prevention of high uric acid levels due to chemotherapy
Management of Tumor Lysis Syndrome (TLS)
Helps protect kidneys from uric acid-related damage
Used in patients with leukemia, lymphoma, and other cancers receiving chemotherapy

🔹 Composition
Active ingredient: Rasburicase 1.5 mg
Belongs to recombinant urate oxidase enzyme class
Used in oncology supportive therapy

🔹 How It Works
Converts uric acid into allantoin, a more easily excreted substance
Rapidly lowers blood uric acid levels
Helps reduce the risk of kidney complications during chemotherapy

🔹 Key Benefits
Effective Tumor Lysis Syndrome management injection
Helps prevent chemotherapy-related kidney complications
Rapid uric acid reduction support
Important supportive medicine in cancer care

🔹 Dosage and Administration
Administered as an intravenous infusion under medical supervision
Dosage is determined by oncologist based on body weight and uric acid levels
Usually given once daily for a limited treatment duration
Requires regular blood monitoring during therapy

🔹 Possible Side Effects
Nausea or vomiting
Fever
Headache
Rash or allergic reactions
Diarrhea
Rare severe hypersensitivity reactions

🔹 Precautions
Use only under strict oncology supervision
Contraindicated in patients with G6PD deficiency
Regular monitoring of uric acid and blood parameters is required
Store under refrigerated conditions (2–8°C)
Inform doctor about allergies or previous infusion reactions